Sponsor

Biothervax SpA

Siena 2457, 7610671

About the sponsor

Biothervax SpA is involved in clinical research on a recombinant Bacillus Calmette-Guérin platform designed to express the RSV nucleoprotein, with attention to vaccine safety and immune response in older adults.

RSV immunogenicity
Recombinant BCG vaccine development
Viral antigen expression

The research focus includes immune recognition of respiratory syncytial virus antigens in adults over 60 years of age.

About Specializations

Biothervax SpA runs clinical trials in conditions such as Respiratory syncytial virus infection, among others.

Respiratory syncytial virus infection

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

1 clinical trial

Respiratory syncytial virus infection

Recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of rBCG-N-RSV Vaccine Compared to BCG Vaccine in Adults Over 60 with Respiratory Syncytial Virus (RSV) Concerns

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years · Healthy volunteers
Sponsor:Biothervax SpA

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →